Ertugliflozin (PF-04971729): Selective SGLT2 Inhibitor for Diabetes and Cardiovascular Research

Executive Summary: Ertugliflozin (PF-04971729, A3715) is a potent, selective inhibitor of sodium-glucose co-transporter 2 (SGLT2), with over 2,000-fold selectivity versus SGLT1, making it a precise tool for diabetes mellitus research (APExBIO product page). It lowers blood glucose by blocking renal glucose reabsorption and offers additional benefits: reduced body weight, improved cardiovascular outcomes, and renal protection in clinical and preclinical models (Nikolaou et al. 2022). Ertugliflozin is effective in animal models at 1–10 mg/kg/day and is clinically administered at 5–15 mg/day orally. It also demonstrates anti-inflammatory and mucosal repair activity in ulcerative colitis models. The compound is soluble in DMSO and ethanol but insoluble in water, and should be stored at -20°C for stability (APExBIO).

Biological Rationale

Type 2 diabetes mellitus (T2D) is characterized by chronic hyperglycemia due to impaired insulin secretion and action. Renal glucose reabsorption via sodium-glucose co-transporter 2 (SGLT2) plays a significant role in maintaining elevated blood glucose in T2D. SGLT2 inhibitors, such as Ertugliflozin (PF-04971729), reduce plasma glucose independently of insulin sensitivity or secretion, offering a mechanistically distinct intervention (Nikolaou et al. 2022). Beyond glycemic effects, SGLT2 inhibition impacts body weight, blood pressure, and cardiovascular and renal endpoints (APExBIO). The SGLT2 pathway is also implicated in inflammatory and fibrotic processes, providing a rationale for its study in ulcerative colitis and heart failure models.

Mechanism of Action of Ertugliflozin (PF-04971729)

Ertugliflozin (PF-04971729) selectively inhibits SGLT2, a transporter located in the proximal renal tubules, preventing the reabsorption of filtered glucose and promoting glycosuria. It exhibits >2,000-fold selectivity for SGLT2 over SGLT1, minimizing off-target intestinal glucose absorption effects (APExBIO). Upon oral administration, Ertugliflozin is absorbed and reaches systemic circulation, exerting effects on renal glucose transport. In preclinical models, Ertugliflozin also inhibits the NF-κB signaling pathway, downregulates miR-155, and promotes M2 macrophage polarization, supporting anti-inflammatory and mucosal repair activities in ulcerative colitis models. These pleiotropic effects extend its relevance beyond glycemic control (Nikolaou et al. 2022).

Evidence & Benchmarks

• Ertugliflozin induces significant urinary glucose excretion and lowers blood glucose in both diabetic and non-diabetic animal models (Nikolaou et al. 2022).
• Clinical dosing (5 mg or 15 mg once daily) achieves marked reductions in HbA1c and body weight in T2D patients (APExBIO).
• At 10 mg/kg/day in animal models, Ertugliflozin demonstrates efficacy comparable to sulfasalazine in ulcerative colitis mucosal repair (APExBIO).
• Cardioprotective effects in non-diabetic mouse models are dose-dependent; infarct size reduction requires double the stoichiometric equivalent dose (20 mg/kg/day), compared to empagliflozin or dapagliflozin (Nikolaou et al. 2022).
• Ertugliflozin’s solubility is ≥50.8 mg/mL in DMSO and ≥51.5 mg/mL in ethanol, but it is insoluble in water (APExBIO).
• Long-term solution storage is not recommended; -20°C storage is optimal for compound stability (APExBIO).

For focused applications in SGLT2-mediated glucose transport study, see PF-04971729 (Ertugliflozin): Reliable SGLT2 Inhibition...—this article extends their workflow guidance by providing peer-reviewed, dose-dependence evidence and mechanistic clarifications. For assay optimization and cell-based compatibility, Ertugliflozin (PF-04971729): Practical Solutions... is complemented here with expanded data on cardiovascular and anti-inflammatory endpoints. The molecular selectivity and transporter specificity discussed in PF-04971729 (Ertugliflozin): Selective SGLT2 Inhibitor fo... are updated here by detailing experimental dose-response and clinical parameters from recent literature.

Applications, Limits & Misconceptions

Ertugliflozin (PF-04971729) is primarily applied in:

• Type 2 diabetes research: As an oral SGLT2 inhibitor, it models renal glucose reabsorption inhibition and glycemic control.
• Cardiovascular protection studies: Used to investigate heart failure and myocardial injury endpoints, with dose-dependent efficacy (Nikolaou et al. 2022).
• Renal protection research: Explores nephroprotective effects in diabetic and non-diabetic settings.
• Ulcerative colitis models: Assesses anti-inflammatory and mucosal repair roles via immune modulation, including miR-155 downregulation and M2 macrophage polarization.

Common Pitfalls or Misconceptions

• Ertugliflozin’s cardioprotective effect is not universal at standard doses; reduction in infarct size in non-diabetic mouse models requires higher dosing (20 mg/kg/day), whereas empagliflozin and dapagliflozin are effective at lower doses (Nikolaou et al. 2022).
• SGLT2 inhibition does not inherently confer STAT-3 or PI3K pathway activation; these are compound- and context-dependent mechanisms (Nikolaou et al. 2022).
• Ertugliflozin is insoluble in water; improper solvent use may yield unreliable results (APExBIO).
• The compound is not suitable for long-term solution storage; degradation or precipitation may occur above -20°C (APExBIO).
• Not all SGLT2 inhibitors exhibit identical off-target or pleiotropic effects; caution is advised when generalizing findings across the class.

Workflow Integration & Parameters

Source and Quality: Ertugliflozin (PF-04971729, SKU A3715) from APExBIO is supplied at ≥98% purity (APExBIO).

Solubility: Prepare stock solutions in DMSO (≥50.8 mg/mL) or ethanol (≥51.5 mg/mL). The compound is insoluble in water.

Storage: Store powder and solutions at -20°C; avoid repeated freeze-thaw cycles. Long-term storage of solutions is not recommended.

Preclinical Dosing: Animal models: 1–10 mg/kg/day orally; 10 mg/kg/day yields robust anti-inflammatory and mucosal repair effects in UC models.

Clinical Dosing Reference: Human dosing is 5 mg or 15 mg once daily, as monotherapy or adjunctive to other agents in T2D with or without atherosclerotic cardiovascular disease (APExBIO).

Assay Compatibility: Compatible with in vitro, ex vivo, and in vivo models for glucose transport, viability, and immunomodulation studies (Practical Solutions for SGLT2 Inhibitor Assays).

Conclusion & Outlook

Ertugliflozin (PF-04971729, A3715) is a highly selective, potent oral SGLT2 inhibitor with robust evidence for glycemic, cardiovascular, renal, and anti-inflammatory effects. Its unique mechanistic and pharmacokinetic profile supports its wide adoption in preclinical and translational workflows. Researchers should apply dose- and context-specific protocols, leveraging validated sources such as APExBIO for reproducible results. For further reading on detailed workflows and troubleshooting, see PF-04971729: Selective SGLT2 Inhibitor Driving Diabetes Mellitus Research, which this article updates with recent evidence on dosing and mechanistic pathways. As SGLT2 inhibitor research evolves, Ertugliflozin remains a reference compound for high-specificity renal glucose transport and inflammation studies.